RAC are also investigating drug combinations in the melanoma pre-clinical (which were not mentioned in the interim results). So we can expect something entirely new in the final results:
The market for Melanoma is dominated by Yervoy (targets CTLA-4) and Opdivo (targets PD-1). It it is expected that PD-1 checkpoint immunotherapy will dominate the market by 2026. https://www.thepharmaletter.com/article/melanoma-drug-sales-set-to-rise-at-5-3-cagr
And, from the investor presentation we know that RAC are specifically looking for PD-1 synergies in melanoma.
- Forums
- ASX - By Stock
- RAC
- Ann: Race Initiates FTO Melanoma Preclinical Study
Ann: Race Initiates FTO Melanoma Preclinical Study, page-164
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.61 |
Change
0.000(0.00%) |
Mkt cap ! $273.4M |
Open | High | Low | Value | Volume |
$1.61 | $1.66 | $1.60 | $207.2K | 127.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 25510 | $1.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 12000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 25510 | 1.600 |
1 | 31000 | 1.590 |
1 | 10000 | 1.585 |
2 | 8233 | 1.560 |
4 | 15571 | 1.550 |
Price($) | Vol. | No. |
---|---|---|
1.640 | 12000 | 1 |
1.655 | 858 | 1 |
1.665 | 352 | 1 |
1.670 | 1845 | 1 |
1.690 | 1085 | 2 |
Last trade - 15.49pm 29/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |